Evoke Pharma (EVOK) Competitors $4.82 -0.08 (-1.63%) Closing price 04:00 PM EasternExtended Trading$4.78 -0.04 (-0.81%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. KLTO, IMA, MAAQ, TENX, KZR, RENB, CVKD, DARE, HOTH, and RNTXShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Klotho Neurosciences (KLTO), ImageneBio (IMA), Mana Capital Acquisition (MAAQ), Tenax Therapeutics (TENX), Kezar Life Sciences (KZR), Lunai Bioworks (RENB), Cadrenal Therapeutics (CVKD), Dare Bioscience (DARE), Hoth Therapeutics (HOTH), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors Klotho Neurosciences ImageneBio Mana Capital Acquisition Tenax Therapeutics Kezar Life Sciences Lunai Bioworks Cadrenal Therapeutics Dare Bioscience Hoth Therapeutics Rein Therapeutics Evoke Pharma (NASDAQ:EVOK) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of EVOK or KLTO? 20.1% of Klotho Neurosciences shares are held by institutional investors. 6.1% of Evoke Pharma shares are held by insiders. Comparatively, 26.7% of Klotho Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is EVOK or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to Evoke Pharma's net margin of -42.07%. Evoke Pharma's return on equity of -99.48% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-42.07% -99.48% -33.58% Klotho Neurosciences N/A -325.88%-242.15% Which has more volatility & risk, EVOK or KLTO? Evoke Pharma has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of 10.78, meaning that its stock price is 978% more volatile than the S&P 500. Does the media refer more to EVOK or KLTO? In the previous week, Klotho Neurosciences had 1 more articles in the media than Evoke Pharma. MarketBeat recorded 2 mentions for Klotho Neurosciences and 1 mentions for Evoke Pharma. Evoke Pharma's average media sentiment score of 1.89 beat Klotho Neurosciences' score of 0.95 indicating that Evoke Pharma is being referred to more favorably in the media. Company Overall Sentiment Evoke Pharma Very Positive Klotho Neurosciences Positive Which has better valuation & earnings, EVOK or KLTO? Evoke Pharma has higher revenue and earnings than Klotho Neurosciences. Evoke Pharma is trading at a lower price-to-earnings ratio than Klotho Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$10.25M0.73-$5.35M-$2.56-1.88Klotho NeurosciencesN/AN/A-$6.15M-$0.45-1.12 SummaryKlotho Neurosciences beats Evoke Pharma on 7 of the 12 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.64M$4.21B$5.70B$10.39BDividend YieldN/A1.39%5.78%4.70%P/E Ratio-1.8810.8375.6026.38Price / Sales0.7316.05536.29234.17Price / CashN/A7.3425.6730.68Price / Book1.023.4512.826.40Net Income-$5.35M-$134.23M$3.29B$276.69M7 Day Performance-5.86%-0.56%1.12%-0.28%1 Month Performance-11.56%2.22%4.54%6.69%1 Year Performance0.21%41.29%68.00%27.61% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.137 of 5 stars$4.82-1.6%N/A+1.9%$7.64M$10.25M-1.884Positive NewsGap UpKLTOKlotho Neurosciences0.3838 of 5 stars$0.51-2.8%N/AN/A$31.89MN/A-1.12N/AIMAImageneBio3.0691 of 5 stars$8.00+0.6%$35.50+343.8%-62.9%$31.84M$9.16M-1.0470News CoverageAnalyst UpgradeMAAQMana Capital AcquisitionN/A$3.91-2.0%N/A+1,756.8%$31.77MN/A0.001TENXTenax Therapeutics2.4511 of 5 stars$6.50-0.5%$18.00+176.9%+108.0%$29.79MN/A-7.079KZRKezar Life Sciences3.6644 of 5 stars$3.80-2.3%$9.00+136.8%-32.9%$28.49M$7M-0.3960Positive NewsHigh Trading VolumeRENBLunai Bioworks0.7682 of 5 stars$0.17+5.6%N/A-97.4%$28.12MN/A-0.2220Stock SplitHigh Trading VolumeCVKDCadrenal Therapeutics2.9787 of 5 stars$13.78+0.7%$32.00+132.2%-3.2%$28MN/A-1.554Insider TradeDAREDare Bioscience2.2206 of 5 stars$2.14+3.9%$10.00+367.3%-36.1%$27.77M$10K-1.0030Positive NewsHOTHHoth Therapeutics2.9343 of 5 stars$1.95-5.8%$4.00+105.1%+89.7%$27.45MN/A-1.824RNTXRein Therapeutics2.4665 of 5 stars$1.19+6.3%$10.00+740.3%N/A$26.10MN/A-0.449High Trading Volume Related Companies and Tools Related Companies KLTO Alternatives IMA Alternatives MAAQ Alternatives TENX Alternatives KZR Alternatives RENB Alternatives CVKD Alternatives DARE Alternatives HOTH Alternatives RNTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVOK Stock Alerts